TFRC and hepatocellular carcinoma: USP22 promotes the proliferation of hepatocellular carcinoma cells via deubiquitinating and stabilising cyclin‐dependent kinase CDK11B, and it inhibits Sorafenib‐induced ferroptosis by decreasing H2BK120ub occupancy at TFRC TSS downstream region.